# VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome

Study · id `cardio:ct-nct04654052` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04654052](<https://clinicaltrials.gov/study/NCT04654052>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04654052

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 637 participants.

## Technical summary

Registry record NCT04654052. Randomized; no masking; primary purpose treatment. Start 2021-07-02 (actual); primary completion 2026-07-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 637 participants (enrolled count; ClinicalTrials.gov record NCT04654052, source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)
- Started: 2021-07-02 (actual) (ClinicalTrials.gov record NCT04654052, source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)
- Primary completion: 2026-07-29 (actual) (ClinicalTrials.gov record NCT04654052, source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)
- Completion: 2026-08-05 (actual) (ClinicalTrials.gov record NCT04654052, source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT04654052, source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04654052-2026-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
- Acronym: VERONICA
- Condition: Acute Coronary Syndrome
- Condition: Acute Myocardial Infarction
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Previous treatment
- Lead sponsor: Fundación EPIC
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Fundación EPIC (`cardio:org-fundacion-epic`)

## Provenance

Content hash: a7c16070e818014b974f8470b204c39a2c079dde0407bcc8cd637a6d99a84e8b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
